Albin Egger, country representative of UCB Pharma Austria, discusses the strong performance of the Austrian affiliate within the global group, organizational restructuring, and the receptiveness of Austria to UCB’s innovative products. Globally, UCB registered nine percent growth for the first nine months of 2017. How would you describe the contribution of the Austrian affiliate to this success?
"In Austria, we will generate higher revenues than in 2016. It has hence been a good year for us"